Navelbine (Vinorelbine Tartrate)

Vinorelbine Tartrate, the active ingredient in Navelbine, is a Vinca alkaloid presented as an oral formulation for oral use. It is employed in the treatment of certain advanced solid tumours, notably non‑small cell lung cancer and metastatic breast cancer in adult patients.

GNH USA supplies Navelbine as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Navelbine is a chemotherapy agent used in the management of solid tumours that rely on microtubule inhibition. - Non‑small cell lung cancer: improves disease control and overall survival when combined with standard regimens. - Metastatic breast cancer: provides tumour reduction and symptom relief in patients with prior therapy. - Advanced or recurrent solid tumours: may be considered as part of combination protocols when other options are limited.

Vinorelbine is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Anemia: decreased red blood cells causing fatigue. - Nausea and vomiting: gastrointestinal upset common after oral dosing. - Constipation: bowel motility reduction. - Fatigue: generalised tiredness. - Alopecia: hair thinning or loss.

Serious or Rare Side Effects: - Severe neutropenia with febrile infection. - Pulmonary toxicity, including interstitial pneumonitis. - Peripheral neuropathy: tingling or numbness in extremities. - Allergic reactions: rash, pruritus, or anaphylaxis. - Cardiac arrhythmias: irregular heart rhythms. - Hepatic dysfunction: elevated liver enzymes or jaundice.

Before initiating therapy, clinicians should assess baseline organ function and monitor patients closely. - Monitor blood counts: perform regular complete blood counts to detect myelosuppression. - Assess liver function: check hepatic enzymes and bilirubin prior to each cycle. - Evaluate pulmonary status: avoid use in patients with pre‑existing severe lung disease. - Use caution in the elderly: dose adjustments may be required due to reduced clearance. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Vinorelbine may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase vinorelbine exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce therapeutic levels. - Concurrent myelosuppressive chemotherapy: markedly heighten bone‑marrow toxicity.

Moderate Interactions (Monitor Closely): - Antiemetics such as ondansetron: may affect QT interval. - Anticoagulants (e.g., warfarin): monitor coagulation parameters. - Diuretics: watch for electrolyte disturbances. - CYP2D6 substrates: potential modest effect on metabolism.